약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 3.

Table. 3.

The analysis of price reductions according to the expansion of reimbursement coverage

Total listed drugs(N=54) Subgroup of listed drugs (N=45)

No. of products Period up to price reduction, mean(year) Reduction rate of price, mean No. of products Period up to price reduction, mean(year) Reduction rate of price, mean
Expansion of reimbursement coverage # 32 - - 24 - -
Products with price reduction 26 4.86 11.65% 20 3.31 11.29%
No. of price reduction
1 16 2.66 7.39% 15 2.36 7.66%
2 5 6.12 19.31% 3 4.64 24.75%
3 3 9.37 20.27% 1 4.16 15.92%
4 2 12.68 13.70% 1 12.76 20.83%

- Increase in No. of indications 25 - - 17 - -
Products with price reduction 22 4.21 10.53% 16 2.72 12.03%
No. of price reduction
1 17 3.40 9.84% 13 2.09 11.50%
2 4 5.86 14.96% 3 5.45 14.32%
3 1 11.18 4.66% - - -

- Expansion of reimbursement criteria 18 - - 12 - -
Products with price reduction 11 7.32 6.47% 7 4.91 4.76%
No. of price reduction
1 7 5.75 4.16% 5 3.62 5.08%
2 4 10.05 10.52% 2 8.13 3.97%

Subgroup include products that have not expired RSA and their patents

#Expansion of reimbursement coverage include increase in number of indications and expansion of reimbursement criteria

Yakhak Hoeji 2021;65:150-7 https://doi.org/10.17480/psk.2021.65.2.150
© 2021 Yakhak Hoeji